{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:16:42Z","timestamp":1790983002127,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,9,10]],"date-time":"2013-09-10T00:00:00Z","timestamp":1378771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:p>Imatinib is the standard of care in chronic meloid leukemia (CML) therapy. However, imatinib is not curative since most patients who discontinue therapy relapse indicating that leukemia initiating cells (LIC) are resistant. Interferon alpha (IFN) induces hematologic and cytogenetic remissions and interestingly, improved outcome was reported with the combination of interferon and imatinib. Arsenic trioxide was suggested to decrease CML LIC. We investigated the effects of arsenic and IFN on human CML cell lines or primary cells and the bone marrow retroviral transduction\/transplantation murine CML model. <jats:italic>In vitro,<\/jats:italic> the combination of arsenic and IFN inhibited proliferation and activated apoptosis. Importantly, arsenic and IFN synergistically reduced the clonogenic activity of primary bone marrow cells derived from CML patients. Finally, <jats:italic>in vivo,<\/jats:italic> combined interferon and arsenic treatment, but not single agents, prolonged the survival of primary CML mice. Importantly, the combination severely impaired engraftment into untreated secondary recipients, with some recipients never developing the disease, demonstrating a dramatic decrease in CML LIC activity. Arsenic\/IFN effect on CML LIC activity was significantly superior to that of imatinib. These results support further exploration of this combination, alone or with imatinib aiming at achieving CML eradication rather than long\u2010term disease control.<\/jats:p>","DOI":"10.1002\/ijc.28427","type":"journal-article","created":{"date-parts":[[2013,8,12]],"date-time":"2013-08-12T05:46:40Z","timestamp":1376286400000},"page":"988-996","source":"Crossref","is-referenced-by-count":31,"title":["Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha"],"prefix":"10.1002","volume":"134","author":[{"given":"Rabab M.","family":"El Eit","sequence":"first","affiliation":[{"name":"Department of Anatomy Cell Biology and Physiology, American University of Beirut Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad N.","family":"Iskandarani","sequence":"additional","affiliation":[{"name":"Department of Anatomy Cell Biology and Physiology, American University of Beirut Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Saliba","sequence":"additional","affiliation":[{"name":"Department of Anatomy Cell Biology and Physiology, American University of Beirut Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark N.","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine American University of Beirut Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami A.","family":"Mahfouz","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine American University of Beirut Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar M.A.","family":"Bitar","sequence":"additional","affiliation":[{"name":"Hematology\u2010Oncology Internal Medicine Lebanese University Faculty of Medical Sciences Sahel General Hospital Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanadi R. El","family":"Ayoubi","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazi S.","family":"Zaatari","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine American University of Beirut Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois\u2010Xavier","family":"Mahon","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matologie et Service des Maladies du Sang CHU de Bordeaux, Universit\u00e9 Victor S\u00e9galen Bordeaux 2, INSERM U876 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues B.","family":"De Th\u00e9","sequence":"additional","affiliation":[{"name":"Service de Biochimie, Equipe labellis\u00e9e Ligue Nationale Contre le Cancer, CNRS\/INSERM\/Universit\u00e9 Paris Diderot UMR 7212, H\u00f4pital Saint Louis Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Bazarbachi","sequence":"additional","affiliation":[{"name":"Department of Anatomy Cell Biology and Physiology, American University of Beirut Beirut Lebanon"},{"name":"Department of Internal Medicine American University of Beirut Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihab R.","family":"Nasr","sequence":"additional","affiliation":[{"name":"Department of Anatomy Cell Biology and Physiology, American University of Beirut Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,9,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61165-9"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326405"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-327437"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330621"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0170"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0117"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2947"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-057521"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-283598"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1891"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0209"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.1.278"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2986"},{"key":"e_1_2_6_18_1","first-page":"2849","article-title":"Arsenic\u2010interferon\u2010alpha\u2010triggered apoptosis in HTLV\u2010I transformed cells is associated with tax down\u2010regulation and reversal of NF\u2010kappa B activation","volume":"96","author":"El\u2010Sabban ME","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101095"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200374"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-211821"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-345702"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.7-suppl_1-30"},{"key":"e_1_2_6_24_1","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V95.3.1014.003k04_1014_1022","article-title":"Arsenic induces apoptosis of multidrug\u2010resistant human myeloid leukemia cells that express Bcr\u2010Abl or overexpress MDR, MRP, Bcl\u20102, or Bcl\u2010x(L)","volume":"95","author":"Perkins C","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07016"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201112044"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.21.1616"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3094"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.10.3074"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.021246"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004095"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.5075"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07815"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35721"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-058-8_15"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.10.3780"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45977"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1947"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10955"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1053\/shem.2002.33612"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.9.772"},{"key":"e_1_2_6_42_1","first-page":"7950","article-title":"Arsenic trioxide inhibits translation of mRNA of bcr\u2010abl, resulting in attenuation of Bcr\u2010Abl levels and apoptosis of human leukemia cells","volume":"63","author":"Nimmanapalli R","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1016311108"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2011.10.001"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0582-0"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn.2251"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a000661"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.9.743"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.02.030"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.04.010"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.patbio.2012.05.010"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.28427","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.28427","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.28427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T19:50:23Z","timestamp":1696362623000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.28427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,10]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1002\/ijc.28427"],"URL":"https:\/\/doi.org\/10.1002\/ijc.28427","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,10]]}}}